Home › Compare › BXPHF vs XYLD

BXPHF vs XYLD: Dividend Comparison 2026

BXPHF yields 5000.00% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXPHF wins by $62217131802825.33M in total portfolio value
10 years
BXPHF
BXPHF
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full BXPHF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — BXPHF vs XYLD

📍 BXPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXPHFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXPHF + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BXPHF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXPHF
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, BXPHF beats the other by $50,882,683,244,271,480,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXPHF + XYLD for your $10,000?

BXPHF: 50%XYLD: 50%
100% XYLD50/50100% BXPHF
Portfolio after 10yr
$31108565901412.69M
Annual income
$29,930,990,143,689,105,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is split right now

BXPHF
No analyst data
Price Target
$0.27
+575.0% upside vs current
Range: $0.27 — $0.27
Altman Z
-4.7
Piotroski
3/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXPHF buys
0
XYLD buys
0
No recent congressional trades found for BXPHF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXPHFXYLD
Forward yield5000.00% ✓10.98%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$62217131802825.35M ✓$25.3K
Annual income after 10y$59,861,980,287,378,210,000.00 ✓$3,219.02
Total dividends collected$62057786341622.61M ✓$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: BXPHF vs XYLD ($10,000, DRIP)

YearBXPHF PortfolioBXPHF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$510,700$500,000.00$10,818$1,098.39+$499.9K → BXPHF
2$24,410,935$23,864,485.98$11,738$1,222.51+$24.40M → BXPHF
3$1,092,192,501$1,066,072,800.30$12,774$1,364.64+$1092.18M → BXPHF
4$45,746,366,951$44,577,720,975.17$13,944$1,527.86+$45746.35M → BXPHF
5$1,793,932,828,410$1,744,984,215,772.56$15,270$1,715.87+$1793932.81M → BXPHF
6$65,871,973,805,320$63,952,465,678,921.49$16,775$1,933.09+$65871973.79M → BXPHF
7$2,265,146,887,602,700$2,194,663,875,631,007.20$18,490$2,184.87+$2265146887.58M → BXPHF
8$72,954,689,148,998,180$70,530,981,979,263,280.00$20,450$2,477.63+$72954689148.98M → BXPHF
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$22,697$2,819.19+$2201076182660.86M → BXPHF
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$25,280$3,219.02+$62217131802825.33M → BXPHF

BXPHF vs XYLD: Complete Analysis 2026

BXPHF — Stock

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

Full BXPHF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this BXPHF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXPHF vs SCHDBXPHF vs JEPIBXPHF vs OBXPHF vs KOBXPHF vs MAINBXPHF vs QYLDBXPHF vs JEPQBXPHF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.